Abstract
The in vitro activities of cefpiramide and apalcillin were compared with those of other third-generation cephalosporins and extended-spectrum penicillins against over 1,000 clinical bacterial isolates. The activity of cefpiramide against Pseudomonas aeruginosa was comparable to those of piperacillin and cefoperazone, inhibiting 90% of strains at concentrations less than or equal to 16.0 micrograms/ml. This drug was also active against a broad range of gram-negative organisms but was generally less active than many of the other cephalosporins tested against members of the family Enterobacteriaceae. The activity of cefpiramide against gram-positive organisms was comparable to that of cefoperazone. Apalcillin, along with ceftazidime, was the most active agent tested against P. aeruginosa and Acinetobacter calcoaceticus subsp. anitratus, inhibiting 90% of these strains at concentrations less than or equal to 8 micrograms/ml. Against other gram-negative and gram-positive organisms, its activity was similar to that of piperacillin. The activities of both cefpiramide and apalcillin were significantly reduced by the presence of several plasmid-mediated beta-lactamases in a series of otherwise isogenic strains of P. aeruginosa in comparison with their activities against a parent strain which lacks these enzymes. Many strains of Enterobacter cloacae were synergistically inhibited by the combination of gentamicin with either cefpiramide (5 of 10 strains) or apalcillin (6 of 10 strains). Most strains of P. aeruginosa were synergistically inhibited by the combination of gentamicin with either cefpiramide (8 of 10 strains) or apalcillin (10 of 10 strains). However, cefoxitin antagonized the activity of both cefpiramide and apalcillin against most of these same strains.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Jones R. N., Ayers L. W., Gavan T. L., Gerlach E. H., Sommers H. M. In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers. Antimicrob Agents Chemother. 1984 May;25(5):669–671. doi: 10.1128/aac.25.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Calderwood S. B., Gardella A., Philippon A. M., Jacoby G. A., Moellering R. C., Jr Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):266–271. doi: 10.1128/aac.22.2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eliopoulos G. M., Gardella A., Moellering R. C., Jr In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother. 1982 Feb;9 (Suppl 100):143–152. doi: 10.1093/jac/9.suppl_c.143. [DOI] [PubMed] [Google Scholar]
- Farber B. F., Eliopoulos G. M., Ward J. I., Ruoff K. L., Syriopoulou V., Moellering R. C., Jr Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother. 1983 Nov;24(5):702–705. doi: 10.1128/aac.24.5.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fass R. J., Helsel V. L. Comparative in vitro activities of apalcillin and piperacillin against gram-negative bacilli. Antimicrob Agents Chemother. 1984 Nov;26(5):660–664. doi: 10.1128/aac.26.5.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fukasawa M., Noguchi H., Okuda T., Komatsu T., Yano K. In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob Agents Chemother. 1983 Feb;23(2):195–200. doi: 10.1128/aac.23.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gootz T. D., Sanders C. C., Goering R. V. Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis. 1982 Jul;146(1):34–42. doi: 10.1093/infdis/146.1.34. [DOI] [PubMed] [Google Scholar]
- Kato M., Inoue M., Mitsuhashi S. Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1982 Nov;22(5):721–727. doi: 10.1128/aac.22.5.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lode H., Elvers A., Koeppe P., Borner K. Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother. 1984 Jan;25(1):105–108. doi: 10.1128/aac.25.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakagawa K., Koyama M., Matsui H., Ikeda C., Yano K., Nakatsuru N., Yoshinaga K., Noguchi T. Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother. 1984 Feb;25(2):221–225. doi: 10.1128/aac.25.2.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Labthavikul P. In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins. Antimicrob Agents Chemother. 1982 Jun;21(6):906–911. doi: 10.1128/aac.21.6.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Noguchi H., Eda Y., Tobiki H., Nakagome T., Komatsu T. PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation. Antimicrob Agents Chemother. 1976 Feb;9(2):262–273. doi: 10.1128/aac.9.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Niles A. C., Murray P. R. In vitro antibacterial activity of cefpiramide. Antimicrob Agents Chemother. 1984 Mar;25(3):368–372. doi: 10.1128/aac.25.3.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]